Antibodies by Design, a division of MorphoSys, and Chimera Biotec have announced the start of a co-marketing agreement between the two companies
Within the scope of the agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and Chimera Biotec's complementary Imperacer assay technology for ultra-sensitive antigen detection.
Each partner will offer the services of the other to its customers throughout the worldwide market.
